Biogen revenue was $14.38 b in FY, 2019 which is a (6.9%) year over year increase from the previous period.
Biogen revenue breakdown by business segment: 15.9% from Anti-CD20 Therapeutic Programs, 79.1% from Product Revenues and 4.9% from Other
|FY, 2017||FY, 2018||FY, 2019|
|Anti-CD20 Therapeutic Programs||1.56 b||1.98 b||2.29 b|
|Product Revenues||10.35 b||10.89 b||11.38 b|
|Other||360 m||585.9 m||707.7 m|
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.